期刊
NATURE
卷 460, 期 7251, 页码 53-U61出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nature08129
关键词
-
资金
- MEC
- DIUE
- Ramon y Cajal program
- ICREA-Academia program
- Ministerio de Educacion y Ciencia [BFU2006-12251, SAF2005-00058, SAF2006-3440]
- Genoma Espana (FANCOGENE)
- European Commission 'Marie-Curie Reintegration Grant' [MIRG-CT-2007-046523]
- European Program CONSERT [LSHB-CT-2004-5242]
- Fondo de Investigaciones Sanitarias [RETIC-RD06/0010/0016, PI061897, PI061099]
- Marato de TV3 [063430]
- G. Harold and Leila Y. Mathers Charitable Foundation
- Fundacion Marcelino Botin
- Fundacion Cellex
- ICREA Funding Source: Custom
The generation of induced pluripotent stem (iPS) cells has enabled the derivation of patient-specific pluripotent cells and provided valuable experimental platforms to model human disease. Patient-specific iPS cells are also thought to hold great therapeutic potential, although direct evidence for this is still lacking. Here we show that, on correction of the genetic defect, somatic cells from Fanconi anaemia patients can be reprogrammed to pluripotency to generate patient-specific iPS cells. These cell lines appear indistinguishable from human embryonic stem cells and iPS cells from healthy individuals. Most importantly, we show that corrected Fanconi-anaemia-specific iPS cells can give rise to haematopoietic progenitors of the myeloid and erythroid lineages that are phenotypically normal, that is, disease-free. These data offer proof-of-concept that iPS cell technology can be used for the generation of disease-corrected, patient-specific cells with potential value for cell therapy applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据